Forest disease virus (KFDV), both classical and the Alkhurma hemorrhagic fever virus (AHFV) subtype, and Omsk 22 hemorrhagic fever virus (OHFV). We tested compounds reported to have antiviral activity against members of 23 the Flaviviridae family for their ability to inhibit AHFV replication. 6-azauridine (6-azaU), 2'-C-methylcytidine (2'-24 CMC), and interferon-α2a (IFNα) inhibited the replication of AHFV and also KFDV, OHFV and Powassan virus. The 25 combination of IFNα and 2'-CMC exerted an additive antiviral effect on AHFV and the combination of IFNα and 26 6-azaU was moderately synergistic. The combination of 2'-CMC and 6-azaU was complex, being strongly 27 synergistic but with a moderate level of antagonism. The antiviral activity of 6-azaU was reduced by the addition 28 of cytidine, but not guanosine, suggesting that it acted by inhibiting pyrimidine biosynthesis. To investigate the 29 mechanism of action of 2'-CMC, AHFV variants with reduced susceptibility to 2'-CMC were selected. We used a 30 replicon system to assess the substitutions present in the selected AHFV population. A double NS5 mutant 31 S603T/C666S and a triple mutant S603T/C666S/M644V were more resistant to 2'-CMC than the wild-type 32 replicon. The S603T/C666S mutant had a reduced level of replication which was increased when M644V was 33 also present, though the replication of this triple mutant was still below that of wild-type. The S603 and C666 34 residues were predicted to lie in the active site of the AHFV NS5 polymerase, implicating the catalytic center of 35
INTRODUCTION

7
Superscript qRT-PCR kit (Life Technologies) and analyzed on an Applied Biosciences 7500 real-time PCR machine 132 (Life Technologies). AHFV RNA was quantitated using forward (5'-CTGAATGGTTGCTCTAGGGAGGAG-3') and 133 reverse (5'-CAGTCCCATGTTTGTCTCACCTCT-3') primers and a probe oligonucleotide (5'-134 CGAAGTGGAGTCATGGAGACGGAACGTGACA-3') from Integrated DNA Technologies (Coralville, IA). 135
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an endogenous control gene; pilot 136 experiments demonstrated that its expression was not significantly altered after 24 h of viral infection (data not 137 shown). Levels of GAPDH RNA were determined using a human control primer-probe set (Life Technologies) . 138 Viral RNA levels were normalized to GAPDH RNA, and expressed relative to infected, vehicle-only controls. EC 50 139 values were determined as in the CPE inhibition assay. 140
141
Virus titer reduction assay 142 A549 cells were seeded, compounds were added, and cells were infected as for the CPE inhibition assay. 24 h 143 later, the cells were frozen at -80 °C. To determine virus titers, cells were frozen and thawed 3 times, and the 144 resulting supernatants were used to determine 50% tissue culture infectious doses (TCID 50 ) using A549 cells (8 145 wells per dilution). Three days post-infection, the cell monolayers were scored for CPE and endpoint virus titers 146 were calculated using the method of Reed and Muench (24) . 147 148
In vitro combination experiments 149
For combination studies, checkerboard matrices of compound dilutions were generated and added to A549 150 cells, seeded as for the CPE inhibition assay. For the compound titrated in the horizontal direction, 8 2-fold serial 151 dilutions were generated. In the vertical direction, 6 2-fold serial dilutions were made. Concentration-response 152 curves for the individual compounds were determined simultaneously. 2'-CMC and 6-azaU were diluted in 153 DMEM, starting from twice the EC 50 as determined in the CPE inhibition assay. IFNα2a was diluted from a 154 8 starting concentration of 10,000 IU/ml in DMEM supplemented with 0.1% bovine serum albumin (BSA, . One h after the addition of compounds, cells were infected with AHFV at an MOI of 0.5 and incubated 156 for 3 days at 37 °C and 5% CO 2 . The antiviral effects of compounds in combination were determined as in the 157 CPE inhibition assay and analyzed using MacSynergy II software (25, 26) . Results were expressed as the mean 158 synergy and antagonism volumes (µM 2 ) calculated at 95% confidence from 3 independent experiments, each 159 with at least 4 replicates. The extent of synergy or antagonism was defined as volumes of µM 2 : <25 were 160 insignificant; 25-50, minor but significant; 50-100, moderate and values >100 indicated strong synergy or 161
antagonism. 162 163
Selection of 2'-CMC-resistant variants 164
To select for AHFV variants with reduced susceptibility to 2'-CMC, a 75 cm 2 flask of A549 cells was infected with 165
AHFV at an MOI of 1, in the presence of 25 µM 2'-CMC. Virus was passed according to the schedule shown in 166 Table 4 , using 75 cm 2 flasks, and transferring 1 mL of medium each time. At the indicated passages, 1 mL 167 samples of the cell culture media were taken, 10 µg of carrier RNA (Life Technologies) was added and total RNA 168 was extracted (PureLink RNA Mini Kit, Life Technologies). A 4 kb fragment spanning the C-terminus of NS4A, 169 NS4B, NS5 and the 3'-UTR was amplified by one-step RT-PCR using the primers Alk7F and alkG1R and the 170 method described previously (27) . The resulting amplicons were treated with RNase Cocktail Enzyme Mix (Life 171 Technologies) for 20 min at room temperature to remove any viral RNA before being transferred from BSL-4 to 172 BSL-2 in TRIzol (Life Technologies), purified and subjected to next generation sequencing using the PacBio 173 platform (Pacific Biosciences, Menlo Park, CA, USA). Sequencing reads were assembled using a reference 174 sequence (accession # JF416954) and variants were quantified using the probalistic variant detection function of 175 the CLC Genomics Workbench 6 (CLCbio, Aarhus, Denmark) with a 1% minimum. The mean coverage at each 176 base was 7497 reads. 177 9 179 180 AHFV reporter replicon 181 cDNA encoding the AHFV reporter replicon was synthesized and cloned in two pieces by GenScript (Piscataway, 182 NJ, USA). Mutations were introduced into the NS5 sequence by site-directed mutagenesis (QuikChange II; 183 Agilent Technologies, Santa Clara, CA, USA). A mutant with an inactivated polymerase (pol-mutant) was 184 generated by mutating the GDD motif of NS5 to RTA, an RsrII restriction site to facilitate identification by 185 restriction digestion. All mutants were verified by Sanger sequencing. To assemble the reporter replicon, each 186 fragment was amplified by PCR and used in overlapping extension PCR to generate the replicon cDNA with a 187 minimal T7 promoter lacking two Gs at the 5' end of the sense strand. These amplicons were used as templates 188 to transcribe capped replicon RNA using the T7 mMESSAGE mMACHINE system (Life Technologies). RNA was 189 assessed by agarose gel electrophoresis and quantitated by spectrophotometry. Replicon RNA was introduced 190 into Huh7 cells by electroporation, using the Neon Transfection System (Life Technologies). Huh7 cells were 191 resuspended at 5 x 10 6 cells/ml in Resuspension buffer (Life Technologies), and 625 ng of replicon RNA added to 192 100 µL cells. Electroporation conditions were 1600 V, 20 ms, 1 pulse and 5 µL of the transfected cell mix was 193 added to 100 µL of medium per well of a 96-well plate. Compounds were added 4 h post-transfection. For 194 harvesting, the medium was removed, the cells were washed once with phosphate-buffered saline (PBS) and 195
Reporter Lysis Buffer (Promega) was added. Samples were frozen at -80 °C and thawed once before luciferase 196 activity was assayed (BrightGlo luciferase assay system, Promega). Luminescence was measured on a Synergy 197 H1MD plate reader (BioTek, Winooski, VT, USA). To account for potential differences in transfection efficiency, 198 luciferase signals were normalized to those from cells harvested 4 h post-transfection. 199
Immunofluorescence 202
To detect AHFV proteins expressed by the reporter replicon, Huh7 cells were electroporated with replicon RNA 203 and incubated for 48 h. Cells were washed with PBS, fixed with 2% (w/v) paraformaldehyde for 10 minutes at 204 room temperature and permeabilized with 0.1% (v/v) Triton X-100 in PBS for 10 min at room temperature. AHFV 205 proteins were detected with anti-AHFV hyperimmune mouse ascites (1:1000 dilution in PBS supplemented with 206 2% w/v BSA) and goat anti-mouse Alexa 488 (1:1000; Life Technologies). Cell nuclei were stained with DAPI. 207
208
Modeling resistant variants 209
A homology model was obtained using one-2-one threading through the Phyre2 Protein Fold Recognition Server 210 (28), using the AHFV RNA-dependent RNA polymerase (RdRp) sequence and the structure of the WNV RdRp 211 domain (Protein Data Bank ID 2HFZ) (29). Percentage identity between the 2 sequences was 63% and the 212 confidence value for the threading returned by Phyre2 was 100%. The UCSF Chimera package was used for 213 molecular graphics (30). 214 215 11
RESULTS
217
Identification of inhibitors of AHFV replication 218
We found that the human lung epithelial cell line, A549, supported robust growth of the tick-borne flaviviruses 219 AHFV, KFDV, OHFV and POWV, yielding 100-to 1000-fold higher titers than Vero E6 cells. This growth was 220 accompanied by a CPE that for AHFV resulted in >95% cell death 3 days after infection at an MOI of 0.5. We took 221 advantage of this CPE to test if compounds reported to have an antiviral effect against other members of the 222
Flaviviridae could inhibit AHFV-induced cell death. Compounds were initially tested at 50 µM and 10 µM, unless 223 otherwise noted. The viability of compound-treated, but mock-infected, cultures was determined 224
simultaneously. 225
Compounds that did not specifically inhibit AHFV-induced CPE included the HCV protease inhibitor telaprevir, 226 the NS5A inhibitor daclatasvir and the non-nucleoside polymerase inhibitor VX-222 (data not shown). Similarly, 227 inhibitors of α-glucosidase (castanospermine, NB-DNJ and DONH), hsp90 (geldanamycin, 17-DMAG and 17-AAG) 228 and cellular kinases (dasatanib, erlotinib, gefitinib and lapatinib at 1 or 10 µM) exhibited no specific antiviral 229 activity. Ezetimibe and ribavirin also exhibited no specific anti-AHFV activity (data not shown). 230 Different 2'-modified nucleosides differ in their potency against HCV (14, 15). We therefore tested a panel of 2'-231 C-and 2'-O-methylated nucleoside analogues for their ability to inhibit AHFV. Dasatanib (10 µM) was used as a 232 positive control for cell death. At 50 µM, none of the tested nucleosides were cytotoxic (Fig. 1B) , and 2'-CMC 233 and 2'-CMA demonstrated an antiviral effect, with 2'-CMC being the more potent (Fig. 1A) . 234
Other compounds with a specific anti-AHFV effect were lycorine (at 1 µM), 6-azaU and IFNα2a. In subsequent 235 testing, the EC 50 for lycorine against AHFV was determined to be 1.7 µM, but it had a detectable cytotoxic effect 236 and an SI of 9 (Table 1 ). An analog of lycorine with anti-WNV activity but with reduced cytotoxicity has been 237 reported (19), and we did not study lycorine itself further. The characterization of the antiviral activities of 2'-238 CMC, 6-azaU and IFNα2a is described below. 239 12 240 241
Characterization of AHFV inhibitors 242
The activity of 2'-CMC against AHFV was investigated further. In the assay for the inhibition of AHFV CPE, the 243 EC 50 of 2'-CMC was determined to be 15.3 µM (Table 1 ). Its antiviral activity was confirmed using qRT-PCR for 244 viral RNA, with an EC 50 of 2.5 µM (Table 1 ) (EC 50 values in our qRT-PCR assay were consistently ~7-fold lower 245 than those determined in the CPE assay, probably due to the shorter time period used in the qRT-PCR assay). 246
The cytotoxicity of 2'-CMC was determined in mock-infected cells using a cell viability assay and by qRT-PCR for 247 GAPDH; SI values were >3.5 and >20, respectively. 2'-CMC inhibited AHFV production in a concentration-248 dependent manner, with 25 µM reducing virus titer by ~4-logs ( Fig. 2A) . We also tested the anti-AHFV activity of 249 PSI-6130, a derivative of 2'-CMC that was over 4-fold more potent than 2'-CMC against the HCV replicon, but 250 was a poor inhibitor of WNV, DENV and YFV (31). PSI-6130 only weakly inhibited AHFV CPE, with an EC 50 of 160 251 µM (Table 1) . 252
The EC 50 of 6-azaU was 1.9 µM in the CPE inhibition assay and 0.33 µM measured by qRT-PCR (Table 1) . 6-azaU 253 was relatively well tolerated by the cells, with no apparent cytotoxic effect and an SI of >154 as determined by 254
qRT-PCR. 6-azaU also mediated a marked concentration-dependent inhibition of AHFV titers (Fig. 2B ). An orally 255 absorbable prodrug of 6-azaU, 6-azaU triacetate, has been used as a treat severe psoriasis. 6-azaU triacetate 256 also inhibited AHFV-induced CPE, but was ~4-fold less potent (Table 1) . 257
For many years, pegylated IFNα2a or IFNα2b were components of the standard of care for hepatitis C. We 258 tested the non-pegylated form of IFNα2a for its ability to inhibit AHFV replication. IFNα2a exhibited antiviral 259 activity, with a somewhat flat dose-response; EC 50 values were 684 and 12.4 IU/mL as measured by the CPE 260 inhibition and qRT-PCR assays, respectively (Table 1) . This activity is similar to that against the HCV replicon (32). 261 IFNα2a produced no detectable cytotoxic effect at up to 160,000 IU/mL. In the AHFV titer assay, however, 262 13 IFNα2a was less effective than 2'-CMC or 6-azaU, with a maximal inhibition of ~1.5 logs at 208,000 IU/mL (Fig.  263   2C) . 264
To confirm that the inhibitory activities of 2'-CMC, 6-azaU and IFNα2a were not specific to A549 cells, each 265 compound was tested for its ability to inhibit AHFV replication in HeLa, HT-1080, Huh7 and VeroE6 cells. Each 266 compound inhibited AHFV replication in a dose-dependent manner, as measured by qRT-PCR, in all cell lines 267 tested (data not shown). 268
269
Activity against other pathogenic tick-borne flaviviruses 270 Next, we tested 2'-CMC, 6-azaU, 6-azaU-triacetate and IFNα2a for their ability to inhibit the replication of other 271 highly pathogenic tick-borne flaviviruses, the hemorrhagic-fever viruses KFDV and OHFV, and the encephalitis-272 associated POWV. The EC 50 values for each compound for each virus were determined using the CPE inhibition 273 assay (Table 2) . 2'-CMC inhibited CPE induced by all of the tested viruses. 6-azaU and 6-azaU triacetate similarly 274 inhibited virus-induced CPE. IFNα2a inhibited AHFV and KFDV less well than POWV and OHFV (the order of 275 susceptibility, ranked from most susceptible to least, being POWV = OHFV > AHFV = KFDV). 276 277
In vitro combination studies 278
Combinations of drugs are used to treat HCV and HIV to help curtail the emergence of resistant mutants and to 279 achieve greater antiviral effects at lower doses. We determined the effects of combinations of compounds on 280 AHFV, using the Bliss independence model and MacSynergy II software (33-35). Checkerboard titrations of pairs 281 of compounds, and each compound alone, were tested for their ability to inhibit AHFV. The calculated 282 theoretical additive antiviral effect was subtracted from the observed effect to reveal a statistically significant 283 greater than expected (synergistic) or less than expected (antagonistic) antiviral effect. No significant 284 cytotoxicity was produced by the tested combinations in mock-infected cells (<15% cytotoxicity at any dilution). 285
14
The combination of IFNα2a with 2'-CMC demonstrated no significant synergy or antagonism, indicating that this 286 combination was additive (Table 3) . When IFNα2a was combined with 6-azaU, a moderate level of synergy was 287 apparent (60.16 µM 2 ). In contrast, the combination of 2'-CMC and 6-azaU yielded a strongly synergistic 288 interaction (228.81 µM 2 ), along with a moderate antagonism (-59.07 µM 2 ). Volumes of > 100 µM 2 are predicted 289 to be significant in vivo, suggesting that of those tested here, only the combination of 2'-CMC and 6-azaU might 290 exert a synergistic effect in patients. 291 292
Mechanisms of action 293
The antiviral activity of 6-azaU has been attributed to its inhibition of OMP decarboxylase and consequent 294 inhibition of cellular pyrimidine synthesis. To test if AHFV inhibition by 6-azaU occurred through this mechanism, 295 we determined whether the addition of uridine, cytidine or guanosine to the culture medium blocked 6-azaU 296 activity. A dose-dependent inhibition of the antiviral effect was observed with increasing concentrations of 297 uridine or cytidine, but not guanosine (Fig. 3) . This is consistent with the hypothesis that 6-azaU inhibits AHFV 298 through the inhibition of cellular pyrimidine synthesis. 299
To investigate the mechanism by which 2'-CMC inhibits AHFV, variants with a reduced susceptibility were 300 selected by passaging the virus 21-times in the presence of increasing concentrations of 2'-CMC for decreasing 301 periods of time (Table 4) . Virus was also passaged without compound, as a mock-selected control. The titer of 302 this mock-selected virus remained constant at approximately 4 x 10 8 TCID 50 /mL over the course of the 303 experiment. In contrast, the titer of AHFV grown in the presence of 2'-CMC was 3 x 10 8 TCID 50 /mL after 8 304 passages, and fell 10-fold to 3 x 10 7 at passage 17, before recovering at passage 21. This suggested that 305 selection occurred between passages 8 and 17 and that a mutant able to replicate in the presence of 2'-CMC 306 arose. We therefore determined the susceptibility of each virus population to 2'-CMC. Mock-selected virus was 307 consistently susceptible to 2'-CMC over the course of the experiment, with an EC 50 of around 8 µM. In contrast, 308
on July 6, 2017 by guest http://aac.asm.org/ 15 virus cultured in the presence of 2'-CMC was sensitive to inhibition at passage 8 (EC 50 10.4 µM), but by passage 309 17 was at least 6-fold less susceptible (EC 50 > 44 µM). 310
Since 2'-CMC inhibits the NS5B polymerase of HCV, we amplified and deep-sequenced PCR products including 311 the NS4B and NS5 regions of the selected AHFV populations from passages 8, 17 and 21. Two differences from 312 the reference sequence arose only in the mock-selected viruses and were not investigated further (Table 5) . 313
Three substitutions were associated with growth in the presence of 2'-CMC. The virus quasispecies at passage 8 314 was identical to the reference sequence, but at passage 17, two substitutions S603T and C666S (NS5 amino acid 315 residue numbering), were present in the majority of the sequence reads (96 and 98%, respectively). A third 316 variant, M644V, was identified in 36% of the reads at passage 17 and in 82% of reads at passage 21. 317
To determine if the mutations observed by deep-sequencing were present in the same viral genomes, the PCR 318 product amplified from the 2'-CMC-selected virus at passage 21 was cloned and six clones were subjected to 319 Sanger sequencing. Of these six, all encoded both the S603T and C666S substitutions. Five of them also 320 contained M644V, and one of these also had NS5 G700S (data not shown). 321 322
Amino acid substitutionsin AHFV that reduced susceptibility to 2'-CMC 323
To test if the mutations in AHFV grown under 2'-CMC selection were responsible for resistance, we developed a 324 reporter replicon system for AHFV (Fig. 4A ). This replicon included the first 27 amino acids of the C protein fused 325 to the N-terminus of firefly luciferase, the EMCV IRES, the first 21 amino acids of the E1 protein fused to the N-326 terminus of NS1 and the genes encoding the remaining non-structural proteins. A T7 promoter sequence was 327 introduced before the 5' untranslated region so that the amplicon could be used as a template for in vitro 328 transcription. When replicon RNA was electroporated into Huh7 cells, luciferase was expressed from the wild-329 type replicon sequence, but not from a mutant in which the polymerase was inactivated by mutagenesis (pol-), 330
on July 6, 2017 by guest http://aac.asm.org/ Downloaded from 16 indicating that the replicon was replication competent (Fig. 4B) . Consistent with this, AHFV proteins were 331 detected by immunofluorescence 48 h post-transfection with only the wild-type replicon (Fig. 4C) . 332
Mutations found in the 2'-CMC-selected AHFV were introduced into the replicon and their effect on replication 333 in the presence of this compound was assessed. 2'-CMC inhibited the luciferase signal from the wild-type 334 replicon in a dose-dependent manner, as expected (Fig. 5A) . Similarly, it inhibited expression from the single 335 mutants S603T, C666S and M644V and the double mutants S603T/M644V and C666S/M644V. 2'-CMC did not, 336 however, inhibit luciferase expression by the double mutant S603T/C666S nor the triple mutant 337 S603T/M644V/C666S. Thus, the presence of both S603T and C666S was required for resistance to 2'-CMC. 338
To assess the replication capacity of each mutant, we compared the luciferase signals 48 hours post-339 transfection, without 2'-CMC (Fig. 5B) . The C666S and M644V mutants yielded signals that were similar to the 340 wild-type. In contrast, the signal from the S603T mutant was approximately 200-fold less than that of the wild-341 type replicon, suggesting that this substitution caused a dramatic defect in replication. Similarly, lower levels of 342 luciferase expression were observed with the double mutants S603T/C666S, S603T/M644V and C666S/M644V. 343
The luciferase signal from the triple mutant, S603T/M664V/C666S was however, greater than that of the double 344 mutants, though still approximately 20-fold less than that of the wild-type sequence. Thus, the M664V change is 345 able to somewhat compensate for the reduced replication caused by the S603T/C666S substitutions. 346
The G700S variant was found in a single clone by Sanger sequencing. The mutant with this change was 347 susceptible to 2'-CMC inhibition and, in the absence of compound, gave luciferase signals similar to those of 348 wild-type (data not shown). Since this substitution was only found in a small proportion of the clones, it was not 349 investigated further. 350
For HCV, the substitution S282T, in the active site of NS5B, is associated with 2'-CMC resistance (15, 36) . We 351 were interested to see where the susbtitutions associated with AHFV resistance to 2'-CMC might be located. 352
Since the structure of AHFV NS5 has not been solved, the AHFV NS5 sequence was modeled on the published 353 structure of the RdRp domain of WNV NS5 (29). This analysis predicted that AHFV S603 is located in the NS5 354 on July 6, 2017 by guest http://aac.asm.org/
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RdRp active site, positioned analogously to HCV S282 (Fig. 6B) . The C666S change is immediately C-terminal to 355 the GDD motif, so it too lies in the active site. The M644V change was predicted to lie away from the active site 356 (Fig. 6C) . 357
Altogether, these data suggest that both the S603T and C666S amino acid changes are required for resistance to 358 2'-CMC and are located in the active site of the AHFV RdRp domain. This combination, however, is associated 359 with a severe replication defect, which can be partially compensated for by the M644V substitution. Currently, no antiviral therapies exist for KFDV, either classical or the AHFV subtype, and OHFV, the highly 363 pathogenic tick-borne flaviviruses that cause human hemorrhagic fevers. We tested compounds previously 364 reported to inhibit members of the Flaviviridae family for their ability to inhibit these viruses; two small 365 molecules (6-azaU and 2'-CMC) and one biologic (IFNα2a) inhibited all three. 366 6-azaU inhibits cellular pyrimidine biosynthesis by inhibition of OMP decarboxylase. It has long been known to 367 inhibit diverse viruses in culture, though it has generally performed poorly in animal models (37, 38), probably 368 because the antiviral effect may be overcome by nucleosides in the diet. Inhibitors of other enzymes in the 369 pyrimidine biosynthetic pathway are similarly active in culture, but not in vivo (39, 40) , leading some to conclude 370 that the pathway is not druggable. Potentially, however, combining an inhibitor of pyrimidine biosynthesis with 371 inhibitors acting through different mechanisms might improve antiviral efficacy in vivo. In particular, an inhibitor 372 of pyrimidine biosynthesis might increase the efficacy of a pyrimidine nucleoside inhibitor. We found that the 373 combination of 6-azaU and 2'-CMC exhibited a complex interaction, with a high level of synergy, but also 374 showing antagonism at some concentrations. The effect of this combination in patients is difficult to predict, but 375 could be synergistic at certain doses. 376 Pegylated IFN-α was a component of the standard-of-care for treating hepatitis C for many years. We found that 377
IFNα2a inhibited the replication of all the tick-borne, hemorrhagic fever-associated flaviviruses tested, though it 378 did not reduce viral titers as effectively as 6-azaU or 2'-CMC (Fig. 2) . A Russian language manuscript previously 379 reported that larifan, an inducer of IFN, was active against OHFV (41). Due to its short half-life, IFN would likely 380 have to be administered immediately prior to, or shortly after, infection. 381
Several 2'-modified nucleoside analogues have been reported to inhibit the HCV replicon (14, 15). 2'-CMC also 382 inhibits YFV and norovirus both in cell culture and in animal models (42-45). 2'-CMC inhibits the HCV 383 polymerase, NS5B, preventing viral RNA synthesis. Due to the poor oral availability of 2'-CMC, a valine ester 384 prodrug, valopcitabine or NM283, was advanced to clinical trials for HCV treatment (46). A twice-daily dose of 385 19 800 mg NM283 reduced the mean HCV load by 1.2 log 10 IU/mL after 14 days, providing proof-of-concept for 386 inhibitors with this mechanism. Subsequently, NM283 was evaluated in combination with pegylated IFN in a 387 phase IIb trial. This combination reduced viral load by >4 log 10 IU/mL after 28 days, but the trial was 388 discontinued due to gastrointestinal side effects. 389
For the flaviviruses, 2'-CMC may be a candidate for lead optimization to generate a non-toxic analogue with 390 greater antiviral potency. Several groups have followed this strategy to develop a nucleoside inhibitor of HCV 391 and multiple 2'-modified nucleosides have advanced to clinical trials for treatment of hepatitis C. Adverse effects 392 led to the discontinuation of a phase IIb trial with a 2'-methyl guanosine nucleotide, BMS-986094 (INX-189), and 393 to the halting of clinical development of two other guanosine derivatives, IDX184 and IDX19368. At the time of 394 writing, RG7128, a prodrug of PSI-6130, is being evaluated in clinical trials and a 2'-modified uridine derivative 395 (PSI-7977, sofosbuvir or Sovaldi) has recently been approved . These experiences in the HCV field suggest that it 396 may be possible to generate analogues of 2'-CMC effective against AHFV and other flaviviruses, though 397 guanosine derivatives should probably be avoided. 398
Understanding the mechanism by which 2'-CMC inhibits AHFV replication is an important step towards the 399 discovery of a more potent analogue. To this end, we identified several amino acid substitutions that were 400 associated with growth of AHFV in the presence of 2'-CMC. The S282T change in the HCV NS5B polymerase 401 conferred a 5-10-fold reduced susceptibility of HCV to 2'-CMC (36). S282 is located in the active site of the 402 polymerase and helps form the surface against which nucleoside triphosphates fit when being incorporated into 403 the RNA chain. The S282T change decreased the affinity of NS5B for 2'-CMC, but was also associated with a loss 404 of replicative fitness, to about 10% of the wild-type. For AHFV, we found that two substitutions in the NS5 RdRp, 405 S603T and C666S, were required to confer resistance to 2'-CMC. The S603T change appeared to be analogous to 406 the S282T substitution in HCV, as they were predicted to be located similarly in the active site of their respective 407
RdRp. This suggests that 2'-CMC probably inhibits AHFV replication in the same way it does HCV, by binding in 408 the active site of the polymerase and blocking viral RNA synthesis. Like HCV NS5B S282T, AHFV NS5 S603T (and 409 20 the double substitution S603T/C666S) was associated with a reduced replication capacity. In the context of 410 S603T/C666S, this was partially compensated for by the addition of M644V. Amino acid changes in HCV that 411 might be equivalent to the C666S and M644V substitutions in AHFV NS5 have not, to our knowledge, been 412 reported. The M644 residue was predicted to lie in a helix (α15 in the WNV structure), some 25 Å away from the 413 GDD motif. Perhaps the M644V substitution could result in a modification of the active site structure, though 414 the mechanism by which this might occur is not obvious. Alternatively, M644V might enhance another function 415 of NS5, such as an interaction with another viral or cellular protein, that could compensate for a polymerase 416 with a reduced activity. Given the likely mechanism of 2'-CMC action against AHFV and its probable binding in 417 the NS5 RdRp active site, a rational structure-guided drug design approach, where 2'-CMC is modeled in the NS5 418 active site, may suggest changes to increase the affinity of the molecule and lead to the discovery of a more 419 potent analogue. 420
The requirement for two amino acid changes within NS5 to confer reduced susceptibility to 2'-CMC is consistent 421 with a high barrier to the development of resistance, as has been described for nucleoside inhibitors of HCV (47, 422 48). The residues in question are highly conserved, with S603 and C666 being completely conserved in all tick-423 borne, hemorrhagic fever flaviviruses (C666S is present in one tick-borne encephalitis virus sequence, and one 424 POWV sequence, accession numbers HM535610 and AF310950, respectively). In contrast, M644V is a frequently 425 occurring polymorphism and is found in most of the tick-borne flaviviruses, including several AHFV sequences. 426
In conclusion, we have identified several compounds with activity against the tick-borne hemorrhagic fever-427 associated flaviviruses. We have recently characterized mouse models for AHFV and KFDV infection (Dodd et al, 428 submitted for publication) and plan to test the compounds for antiviral activity in these models. These 429 compounds, even if not clinically effective, may be research tools, or starting points for drug development 430 efforts. Structure-activity relationships have been established for 2'-modified nucleosides against the HCV NS5B 431 polymerase, but to our knowledge, have not yet been investigated for other flaviviruses. The potential for a 2'-432 21 modified nucleoside to be a broad-spectrum inhibitor of flaviviruses is intriguing. Finally, the AHFV reporter 433 replicon described here may be a useful tool for studying AHFV replication under BSL- (A) Inhibition of AHFV-induced cell death. 2'-modi ed nucleoside analogues were dissolved in DMSO and added to A549 cells to a nal concentration of 50 µM and 0.5% DMSO. Cells were infected with AHFV at a multiplicity of infection (MOI) of 0.5, incubated for 3 days, and cell viability was determined. (B) E ect of 2'-modi ed nucleosides on cell viability. A549 cells were treated as in (A), but were mockinfected. Cell viability was measured 3 days after the addition of compound. Cells were treated with 10 µM dasatanib at as a positive control to inhibit cell viability. Mean values from four replicate wells are shown, error bars indicate the standard error of the mean. A representative of three independent experiments is shown. Abbreviations: DMSO, dimethylsulfoxide; 2'-CMA, 2'-C-methyladenine; 2'-CMC, 2'-C-methylcytidine; 2'-CMG, 2'-C-methylguanine; 2'-CMU, 2'-C-methyluridine; 2'-OMA, 2'-O-methyladenine; 2'-OMC, 2'-O-methylcytidine; 2'-OMG, 2'-O-methylguanine; 2'-OMU, 2'-O-methyluridine. The antiviral e ect of 6-azaU is inhibited by uridine or cytidine, but not guanosine. A549 cells were treated with 4 µM 6-azaU and diluent (black bar) or with varying concentrations of uridine (white columns), cytidine (shaded columns) or guanosine (cross-hatched columns). The cells were then infected with AHFV at an MOI of 0.5, then incubated for three days before cell viability was determined. Mean values from eight replicate wells are shown, error bars indicate the standard deviation. 
